Nasdaq · CIK 0001157075
PMCB PharmaCyte Biotech, Inc.
Insider trading from SEC Form 4. Last filing Dec 12, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at PharmaCyte Biotech, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Michael M Abecassis director | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 39,167 | Dec 12, 2025 |
| Dec 12, 2025 | Jonathan Schechter director | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 200,000 | Dec 12, 2025 |
| Dec 12, 2025 | Joshua Silverman CEO and President | AGrant or award Common Stock | +575,000 | $0.00 | $0 | 575,000 | Dec 12, 2025 |
| Dec 12, 2025 | Wayne Remell Walker director | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 37,500 | Dec 12, 2025 |
| Dec 12, 2025 | Robert Weinstein director | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 75,000 | Dec 12, 2025 |
| Dec 12, 2025 | Michael M Abecassis director | FTax withholding Common Stock | -16,875 | $1.02 | $17k | 22,292 | Dec 12, 2025 |
| Dec 12, 2025 | Jonathan Schechter director | FTax withholding Common Stock | -67,500 | $1.02 | $69k | 132,500 | Dec 12, 2025 |
| Dec 12, 2025 | Joshua Silverman CEO and President | FTax withholding Common Stock | -258,750 | $1.02 | $264k | 316,250 | Dec 12, 2025 |
| Dec 12, 2025 | Wayne Remell Walker director | FTax withholding Common Stock | -16,875 | $1.02 | $17k | 20,625 | Dec 12, 2025 |
| Dec 12, 2025 | Robert Weinstein director | FTax withholding Common Stock | -33,750 | $1.02 | $34k | 41,250 | Dec 12, 2025 |
| Apr 25, 2025 | Jonathan Schechter director | AGrant or award Stock Option (Right to Buy)derivative | +63,233 | $0.00 | $0 | 63,233 | Dec 12, 2025 |
| Apr 25, 2025 | Wayne Remell Walker director | AGrant or award Stock Option (Right to Buy)derivative | +63,233 | $0.00 | $0 | 63,233 | Dec 12, 2025 |
| Apr 25, 2025 | Robert Weinstein director | AGrant or award Stock Option (Right to Buy)derivative | +63,233 | $0.00 | $0 | 63,233 | Dec 12, 2025 |
| Apr 25, 2025 | Michael M Abecassis director | AGrant or award Stock Option (Right to Buy)derivative | +63,233 | $0.00 | $0 | 63,233 | Dec 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Michael M Abecassisdirector
- Jonathan Schechterdirector
- Joshua SilvermanCEO and President
- Wayne Remell Walkerdirector
- Robert Weinsteindirector, cfo, officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.